Latest news

03-25

International Journal of Dermatology Publication: NETs as Targets for Hidradenitis Suppurativa Therapy

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterised by recurrent, painful skin lesions which may lead to irreversible

02-25

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces

02-25

International Day of Women and Girls in Science

February 11th marks the International Day of Women and Girls in Science. In celebration of this occasion, we invited three

01-25

Employee Spotlight – Dorus Wilderbeek

Dorus Wilderbeek, the Sr. Project Manager responsible for Citryll's upcoming Phase 2a clinical trial in Rheumatoid Arthritis, joined our company

12-24

Reflections on a Transformative Year at Citryll

As we approach the holiday season and the end of 2024, I wanted to take a moment to reflect on

12-24

Citryll Raises EUR 85 Million Series B To Advance Novel NET-Targeting Therapy For Immune-Mediated Inflammatory Disorders

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces

10-24

Citryll and Leading Rheumatology Centres Receive ReumaNederland Grant to Collaborate on NET Research to Advance Novel Treatments for Rheumatoid Arthritis

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces a ground-breaking collaboration with leading

08-24

A Year in Review: An Interview with Citryll’s CEO

Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this

07-24

Citryll Completes Patient Dosing In The Repeat Dose Stage Of The Phase 1 Trial

The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial

02-24

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after

09-23

Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO

Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.

03-23

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.